Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||23%|
|1 Day Vol Adjusted Return||-0.6|
|1 Month Vol Adjusted Return||-3.7|
|3 Month Vol Adjusted Return||-2.4|
|6 Month Vol Adjusted Return||-9.0|
|20 Days SMA Price ZScore||-2.0|
|50 Days SMA Price ZScore||-1.6|
|12 -26 Days PPO||-5.2|
|1 Month Average Short Volume Ratio||46.5|
|1 Day Volume Change ZScore||-0.3|
|1 Month Daily Vol||10.9|
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/bcli.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference.
The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently provide the threshold of substantial evidence to support the marketing application. Also, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a marketing application submission. "Brainstorm will first consult with principal investigators, ALS experts, expert statistician...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evid...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) to review specific aspects of the company's planned manufacturing modifications to support the development of a semi-automated commercial manufacturing process for NurOwn® (MSC-NTF cell). The meeting included a detailed review of the requirements for comparabi...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on NurOwn® in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) recently provided a corporate update that included information on NurOwn® and its potential regulatory path for amyotrophic lateral sclerosis (ALS). In November 2020, the company announced topline results from the Phase 3 clinical trial of
BrainStorm Cell Therapeutics' (NASDAQ: BCLI) stock price shot up by nearly 30% today, on the one-two punch of an encouraging metric or two in its quarterly results and an update about its most promising pipeline drug. For BrainStorm's Q4 of 2020, the clinical-stage biotech said that its net loss deepened to $31.8 billion, from the year-ago shortfall of nearly $23.3 million. What was likely a stronger tailwind for the stock on Thursday was BrainStorm's news about NurOwn, its treatment that orig...